Organon & Co | OGN - Cash And Equivalent


Organon & Co reported $672M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Celltrion KRW 29.65B 799.42B Jun/2025
Cspc Pharmaceutical CNY 7.57B 793.73M Jun/2025
Deva Holding AS TRY 775.92M 574.67M Sep/2023
Dianthus Therapeutics USD 51.09M 4.9M Dec/2025
Divis Laboratories Ltd INR 4.15B 31.87B Mar/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Kangmei Pharma CNY 1.18B 278M Sep/2025
Knight Therapeutics CAD 81.88M 4.06M Sep/2025
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Medical Developments International AUD 17.84M 219K Jun/2025
Merck USD 18.17B 10.16B Sep/2025
Neuren Pharmaceuticals AUD 5.91M 2.76M Jun/2025
Novartis USD 9.56B 2.9B Sep/2025
Organigram Holdings CAD 28.2M 7.68M Sep/2025
Organon & Co USD 672M 73M Sep/2025
Pharma Mar EUR 17.82M 3.78M Dec/2025
Qiagen NV USD 1.36B 621.78M Sep/2025
Sartorius EUR 389.9M 429.1M Sep/2025
Sino Biopharmaceutical CNY 3.38B 2.09B Dec/2024
Tilray USD 264.83M 43.16M Jun/2025